TheraRadar
Data updated: May 26, 2026

ACCOLATE (zafirlukast)

Leukotriene Receptor Antagonists Trial Activity: Stable 1 active trials
Respiratory Approved 1996-09-26

ACCOLATE is indicated for the treatment of Asthma.

Source: FDA Label • STRIDES PHARMA INTL

Development Insights

Beth Israel Deaconess Medical Center conducting 1 trials (33%)
3 indications explored (Focused)
ovarian cancer (1 trials)
allergy to cats (1 trials)
breast cancer (1 trials)
3
Indications
--
Phase 3 Trials
29
Years on Market

Details

Status
Prescription
First Approved
1996-09-26
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: ZAFIRLUKAST

ACCOLATE Approval History

1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
56 FDA actions from 1996 to 2016 · 2 indication expansions
Mar 2016 SUPPL
Mfg · Manufacturing (CMC)
Nov 2013 SUPPL
Label · Labeling
May 2013 SUPPL
Mfg · Manufacturing (CMC)

What ACCOLATE Treats

1 indications

ACCOLATE is approved for 1 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Asthma
Source: FDA Label

ACCOLATE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ACCOLATE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADVAIR HFA
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
AIRDUO RESPICLICK
FLUTICASONE PROPIONATE
1 shared
Teva
Shared indications:
AIRSUPRA
ALBUTEROL SULFATE
1 shared
AstraZeneca
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT04339140 results posted 19-814 1R21CA231000-01A1 Ph 2 completed Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
NCT06069063 ACC001 Ph 2 not yet recruiting Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
NCT02950480 results posted 15754 Ph 2 terminated Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ACCOLATE FDA Label Details

Indications & Usage

FDA Label (PDF)

ACCOLATE is indicated for the treatment of Asthma.

Track ACCOLATE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment